Deltarasin is primarily researched for its potential in cancer therapy, particularly targeting pancreatic cancer. It works by inhibiting the interaction between KRAS and PDEδ, a process crucial for the localization and function of KRAS proteins, which are often mutated in various cancers. By disrupting this interaction, Deltarasin can potentially halt the growth and proliferation of cancer cells. Its application is still largely in the experimental and preclinical stages, with studies focusing on its efficacy, safety, and potential as a targeted therapeutic agent. Researchers are also exploring its use in combination with other treatments to enhance its anticancer effects.